GE Vernova Inc vs Zoetis Inc — how do they compare? GE Vernova Inc trades at $1,001.75 (market cap $266.16B), while Zoetis Inc trades at $74.55 (market cap $30.20B). The key difference: GE Vernova Inc is far larger — about 8.8× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Zoetis Inc for 70 Days on average.
| GEV | ZTS | |
|---|---|---|
Market Cap | $266.16B | $30.20B |
Volume | 2,324,165 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $1.17K | $147.53 |
52-Week Low | $547.96 | $69.09 |
Typical Hold Time | 36 Days | 70 Days |
Enterprise Value | $255.83B | $37.76B |
Dividend Yield | 0.2% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,007.77, up 1.07% with strong bullish technical momentum. The stock shows impressive fundamental growth with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and a $176B backlog. Analyst consensus remains strongly bullish with 22 buy ratings and a $1,270 price target, representing 26% upside potential from current levels.
The outlook remains positive given the company's positioning in AI-driven power infrastructure demand, though valuation multiples appear elevated with P/E at 28.65 and EV/EBITDA at 85.22. Key risks include execution challenges in the wind segment and competitive pressures in the nuclear energy space. The stock's recent 45% YTD gain suggests much optimism is already priced in, requiring continued strong execution to justify further upside.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →